Vasculitis & polymyalgia rheumatica
Comparative Effectiveness of Tocilizumab and Tumor Necrosis Factor Inhibitors in Takayasu Arteritis: Age‐Related Differences in Treatment Response
Authors' conclusion
TNFi and TCZ demonstrated similar effectiveness in TAK.
Study context
- Population
- Patients with TAK from two independent cohorts (cohort A = 57; cohort B = 94)
- Participants
- 129 vs 56
- Exposure
- Tumor necrosis factor inhibitors (TNFi) vs tocilizumab (TCZ) in TAK
- TNFin = 129
- TCZn = 56reference
- Outcome
- Clinical response to TNFi or TCZ
Methodological detailstwo independent cohorts, prospective subset with standardized research protocol, comparative effectiveness
- Two independent cohorts
- Prospective subset with standardized research protocol
- Comparative effectiveness
Main finding
As reported in the abstract
P = 0.17
Observational data: associations, not effects.
Further findings
Physician global assessment (PGA), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), FDG-PET outcomes (prospective subset)
- No significant differences (P > 0.30)
Clinical response after changing to another TNFi or switching between TNFi or TCZ after treatment failure
- Clinical response
- 31 of 33 (94%)
Median age at onset, TNFi responders vs nonresponders
- Responders vs nonresponders (younger in responders), P = 0.0039
- 23 vs 33.5 years
Median age at onset, TCZ responders vs nonresponders
- Responders vs nonresponders (older in responders), P = 0.0043
- 35 vs 21.5 years
Cytokines in patients with onset <30 years vs controls
- Elevated IL-6 and TNF vs controls; pattern not observed in older patients
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →